About
Remogliflozin etabonate is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and lowered blood glucose levels. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the levels of incretin hormones, thereby increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. This combination therapy offers a complementary approach to managing type 2 diabetes by targeting different mechanisms involved in glucose homeostasis. It aims to provide comprehensive glycemic control, reduce HbA1c, and improve overall metabolic parameters in patients when diet and exercise alone are insufficient, contributing to better long-term health outcomes.
Uses
- Treatment of type 2 diabetes mellitus.
- Improvement of glycemic control.
- Used as an adjunct to diet and exercise.
- Reduction of HbA1c levels.
Directions For Use
Take orally as directed by your physician, usually once or twice daily, with or without food.
Benefits
- Dual mechanism for effective glucose lowering.
- Potential for modest weight loss.
- Low risk of hypoglycemia when used alone.
- Improved insulin sensitivity.
- Reduced glucose reabsorption.
- Comprehensive glycemic control.
Side Effects
- Urinary tract infections (UTIs)
- Genital yeast infections
- Increased urination
- Headache
- Nasopharyngitis
- Dizziness
- Hypoglycemia (especially with other agents)
- Ketoacidosis (rare, with SGLT2 inhibitors)
- Pancreatitis (rare, with vildagliptin)
- Arthralgia
- Peripheral edema
- Constipation
Safety Measures
- Alcohol - Limit alcohol intake as it may increase the risk of dehydration and, rarely, ketoacidosis.
- Pregnancy - Not recommended during pregnancy due to potential risks to the fetus. Consult a doctor to discuss alternatives.
- Breastfeeding - Not recommended as both drugs may be excreted in breast milk. Consult a doctor for advice.
- Liver - Use with caution in patients with liver impairment. Vildagliptin is not recommended in severe hepatic impairment.
- Kidney - Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustment may be needed for moderate impairment.
- Lung - Generally safe for lung conditions. No specific pulmonary precautions.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!